Chlorobutanol

Evidence Level: L5

Predicted Indications: 10

Chlorobutanol
Chlorobutanol: From Sedative, Local Anaesthetic and Preservative Use to Erectile Dysfunction

## Pharmacist Assessment Report

Chlorobutanol: From Sedative, Local Anaesthetic and Preservative Use to Erectile Dysfunction

One-Sentence Summary

Chlorobutanol is a sedative/hypnotic, local anaesthetic and preservative. It is registered in South Africa in a topical cream, Viocort. The TxGNN model predicts it may be effective for erectile dysfunction, but the prediction rests on graph-based scoring only. No clinical trials or publications studying chlorobutanol in this condition were found. The two retrieved trials are unrelated prostate cancer studies.

Quick Overview

Item	Content
Original Indication	Not stated in the SAHPRA registration record (see Why is This Prediction Reasonable? for known pharmacological uses)
Predicted New Indication	Erectile dysfunction
TxGNN Prediction Score	99.79% (TxGNN rank 1500)
Evidence Level	L5
South Africa Market Status	Marketed
Number of SAHPRA Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Based on known information, chlorobutanol acts as a sedative/hypnotic, local anaesthetic and preservative. It has no known pro-erectile mechanism.

The evidence review found no credible mechanistic link between chlorobutanol and erectile dysfunction. The high TxGNN score reflects patterns in the knowledge graph, not clinical or preclinical findings. Until independent evidence appears, the prediction should be treated as a hypothesis only.

The model’s other top predictions are migraine disorders, Tourette syndrome, trichotillomania, ADHD and several rare skin or genetic conditions. All are also L5 with no supporting studies. The only mechanistic argument, for migraine, is a speculative overlap with neuronal excitability.

Clinical Trial Evidence

Both trials retrieved were graded as unrelated to chlorobutanol and to erectile dysfunction.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02286921	Phase 2	Completed	222	Bipolar androgen therapy vs. enzalutamide in castration-resistant metastatic prostate cancer. Chlorobutanol is not involved.
NCT02090114	Phase 2	Completed	112	Sequential bipolar androgen therapy followed by enzalutamide or abiraterone in prostate cancer. Chlorobutanol is not involved.

No SANCTR or PACTR registrations were identified.

Literature Evidence

Currently no related literature available for chlorobutanol in erectile dysfunction.

South Africa Market Information

Registration Number	Product Name	Dosage Form	Approved Indication
G1781 (ACT 101)	Viocort	Cream (topical)	Not stated in the registration record

Only a topical cream is registered, so no registered product covers a route that would clearly suit a systemic indication. Route compatibility for erectile dysfunction has not been assessed.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is model-only (L5). There are no relevant trials or publications, and no plausible mechanism links chlorobutanol to erectile dysfunction. The high score alone does not justify further investment.

To proceed, the following is needed:

The SAHPRA-approved PI (indications, warnings, contraindications), which is currently missing and blocks any safety screening
Mechanism of action data, for example from DrugBank
Independent preclinical or clinical evidence linking chlorobutanol to erectile dysfunction
A route and formulation assessment, since only a topical cream is registered
Re-evaluation of whether any other predicted indication has better support
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.